Table 2 Review of literature on anti-MOG antibodies in adult NMO/NMOSD
From: Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
Publication | MOG+ NMO (SD) (%AQP-seroneg.) | Assay | Characteristics of MOG+ NMOSD patients | ||
|---|---|---|---|---|---|
Gender (%fem.) | Clinical presentation/MRI | Outcome (median f/u in months) | |||
Mader [8] | n = 10 | CBA | 70 | n.a. | n.a. |
(39%) | |||||
Kezuka [9] | n = 8 | ELISA | n.a. | n.a. | No improvement of visual acuity |
(57%) | |||||
Kitley [10] | n = 4 | CBA | 25 | Monophasic simultaneous or sequential TM and ON; lower spinal cord involvement on MRI | Excellent recovery (12) |
(15%) | |||||
Sato [13] | n = 16 | CBA | 38 | More restricted phenotype (ON > TM); bilateral simultaneous ON; single attack; lower spinal cord involvement on MRI | Good recovery in 88% (24) |
(21%) | |||||
Kitley [12] | n = 9 | CBA | 44 | Simultaneous/sequential ON/TM; conus and deep gray nuclei involvement on MRI | Better outcomes; less risk for disability (18) |
(35%) | |||||
Höftberger [16] | n = 16 | CBA | 53 | Higher frequency of involvement of all spinal cord regions | Better outcomes; less risk for disability (67) |
(16%) | |||||
Ramanathan [14] | n = 9 | CBA | 67 | Strong association with BON; optic disk swelling | Propensity to relapse (28) |
(39%) | |||||